Cryotherapy can destroy certain skin cancers, and it does so with reported five-year cure rates above 96% for select tumor types. But the word “certain” is doing a lot of work in that sentence. Whether freezing is the right call depends on the kind of skin cancer, how deep it goes, where it sits on the body, and whether it has been treated before. For straightforward, low-risk non-melanoma skin cancers, cryotherapy is a legitimate and well-studied option. For aggressive or recurrent tumors, it falls short of what surgery can offer.
What Cryotherapy Actually Does to a Tumor
The procedure typically uses liquid nitrogen, which chills tissue to around minus 60°C within seconds of contact. A clinician either sprays the nitrogen directly onto the lesion or applies it with a metal probe. The extreme cold forms ice crystals inside and between cells, rupturing their membranes. When the tissue thaws, fluid rushes in and causes further damage, and small blood vessels in and around the tumor are destroyed, cutting off its supply. The combination of direct cell killing and blood-supply loss is what eliminates the cancer.
Most protocols call for at least two freeze-thaw cycles per session, because a double freeze produces substantially more tissue destruction than a single pass. Research on cryotherapy in liver tissue, for example, showed that double-freeze cycles caused peak cell-damage markers nearly three times higher than single cycles.
1PubMed. Hepatic cryotherapy: double-freeze cycles achieve greater hepatocellular injury in manThe skin is then left to heal on its own. A blister usually forms, followed by a scab that falls off over a few weeks. No stitches, no cutting, no operating room.
Where Cryotherapy Works Best
Cryotherapy’s strongest track record is against precancerous actinic keratoses, the rough, scaly patches that develop on sun-exposed skin and can progress to squamous cell carcinoma if left alone. For isolated actinic keratoses, cryotherapy is considered a standard first-line treatment. One observational study comparing cryotherapy with photodynamic therapy and the topical cream imiquimod found that cryotherapy cleared about 71% of lesions, with the lowest recurrence rate of the three treatments at roughly 3.5%.
2PubMed Central. Treatment of Actinic Keratosis: The Best Choice through an Observational StudyFor actual skin cancers, the picture is more specific. Basal cell carcinoma (BCC), the most common form of skin cancer, responds well to cryotherapy when the tumor is small, superficial, and well-defined. A case-report review noted that cure rates as high as 95% have been reported for low-risk BCC subtypes, and the technique is particularly useful over cartilaginous areas like the nose and ears, where surgery can be complicated.
3PubMed Central. Cryotherapy as an Effective therapeutic Option in Patients with Nodular Basal Cell carcinoma – Case ReportA randomized trial of superficial BCC put the one-year clearance rate for cryosurgery at 100%, compared with about 96% for curettage (scraping the tumor off).
4PubMed Central. Curettage vs. cryosurgery for superficial basal cell carcinoma: a prospective, randomised and controlled trialIn a larger, longer-term review of 684 non-melanoma skin cancers treated with cryosurgery, the five-year cure rate was 99% for basal cell carcinomas and about 96% for squamous cell carcinomas, with an overall rate near 99%.
5PubMed. The five-year cure rate achieved by cryosurgery for skin cancerWhere It Falls Short
Those encouraging numbers apply to carefully selected tumors. When the selection criteria loosen, so do the outcomes. Bowen’s disease, a form of squamous cell carcinoma in situ (meaning it has not yet invaded deeper tissue), illustrates the limits. One study found cryotherapy cleared only about 73% of Bowen’s disease lesions, and recurrence hit roughly 23%.
6PubMed Central. Analysis on the Effectiveness and Characteristics of Treatment Modalities for Bowen’s Disease: An Observational StudyA separate retrospective study tracking squamous cell carcinoma in situ over about eight years reported a cryotherapy recurrence rate of nearly 5%, which sounds reasonable until you compare it to surgical excision’s recurrence rate of under 1%.
7Acta Dermato-Venereologica. A Retrospective Study of Treatment of Squamous Cell carcinoma In situFor recurrent basal cell carcinomas, tumors that have already been treated once and come back, the gap widens considerably. A comprehensive literature review found a recurrence rate of about 13% for cryotherapy on previously treated BCCs, compared with 5.6% for Mohs micrographic surgery. No five-year cryotherapy data were even available for this category at the time of the review; the 13% figure came from studies with shorter follow-up periods.
8PubMed. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinomaThe underlying problem is that cryotherapy cannot tell you whether the cancer is completely gone. Surgery allows a pathologist to examine the removed tissue under a microscope and confirm clear margins. With cryotherapy, the destroyed tissue stays in place and eventually sloughs off, so there is no specimen to check. For well-defined, low-risk lesions, this is an acceptable trade-off. For anything aggressive, deep, or recurrent, that blind spot becomes a real liability.
Melanoma Is Off the Table
When most people worry about skin cancer, they are thinking about melanoma, the type most likely to spread and become life-threatening. Cryotherapy is not a treatment for melanoma. Melanoma demands complete surgical excision with confirmed margins, and often requires additional workup to check whether it has spread to lymph nodes or beyond. Freezing a melanoma could destroy the surface without eliminating deeper cells, and it would also make future biopsy and staging much harder. The one area where cryotherapy intersects with melanoma research is more experimental and concerns the immune system, which is covered below.
How Cryotherapy Compares to Surgery on Cosmetic Results
One argument for cryotherapy is that it avoids a surgical scar. The reality is more nuanced than that sales pitch suggests. A study comparing cosmetic outcomes of cryosurgery versus surgical excision for basal cell carcinomas on the head and neck found that clinical professionals rated surgical results as significantly better looking. Patients also preferred how excision sites healed. Interestingly, a beautician evaluating the same outcomes had no preference for either treatment.
9PubMed. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neckOne critical review went further, arguing that the degree of freezing aggressive enough to reliably destroy non-melanoma skin cancer produces adverse effects and cosmetic outcomes poor enough to negate cryotherapy’s convenience.
10Clinics in Dermatology. Topical treatments for nonmelanoma skin cancer: A literature reviewThat is an overstatement for superficial, small lesions, where cryotherapy often heals neatly. But it highlights a genuine tension: the harder you freeze to ensure the cancer is gone, the worse the cosmetic outcome tends to be. Deep or prolonged freezes are more likely to leave lasting marks, both in texture and in color.
Side Effects and Risks Worth Knowing About
The most common side effects are mild and expected: pain during the procedure, swelling, blistering, and weeping in the days afterward. These resolve without treatment for most people. But there are less-obvious complications worth understanding before you agree to the procedure.
Pigment Changes
Cryotherapy frequently alters skin color at the treatment site, and the change can be permanent. Research into pigment changes after freezing found that even brief freezes caused persistent hypopigmentation (lighter-colored patches). After longer freezes, the consistent finding was that pigment-producing cells were present but not functioning normally, leaving the skin pale.
11PubMed. Pigment changes in human skin after cryotherapyThis matters more for people with darker skin, where a white patch at the treatment site will be much more visible. It is one reason some dermatologists steer patients with deeper skin tones toward other options, even for lesions where cryotherapy is technically effective.
Nerve Damage
Peripheral nerves are sensitive to cold, and freezing tissue near a nerve trunk can cause numbness, tingling, or outright loss of sensation. A study of patients who had cryotherapy near the lower jaw found that every patient experienced altered sensation in the nerve distribution immediately afterward. Most had persistent tingling, while two had complete numbness. It took an average of about 91 days for sensation to improve, with some cases dragging on for over seven months.
12PubMed. Neurosensory changes after liquid nitrogen cryotherapyEven a seemingly simple freeze can cause significant nerve trouble in the wrong location. One case report described ulnar nerve damage from cryotherapy for a common wart near the elbow, resulting in both sensory and motor problems in the hand.
13PubMed. Ulnar neuropathy after liquid nitrogen cryotherapyThese cases do not mean cryotherapy is dangerous as a rule. They mean that the location matters as much as the diagnosis. A small basal cell carcinoma on the forehead is a very different proposition from one sitting right on top of a major nerve.
What the Freeze-Thaw Cycle Feels Like in Practice
Patients typically describe the freezing itself as a sharp, stinging cold that intensifies over a few seconds and then gives way to a deep ache. The thaw is often more uncomfortable than the freeze. Research comparing liquid nitrogen with liquid nitrous oxide found that liquid nitrogen drops skin temperature to about minus 60°C within five seconds, while nitrous oxide reaches about minus 35°C. Both require roughly five minutes to return to normal skin temperature.
14Oxford Academic (Clinical and Experimental Dermatology). Skin thermal recovery following cryotherapy: a comparison of liquid nitrogen and liquid nitrous oxideA treatment session for a single small lesion takes only a few minutes. No anesthesia is usually required, though some clinicians offer a local anesthetic for larger or more sensitive areas. The treated spot will blister, sometimes dramatically, within a day or two. The blister flattens, crusts over, and the dead tissue falls away over two to six weeks depending on the depth of the freeze. During that healing window, you keep the area clean and covered to avoid infection.
Who Is a Good Candidate
Cryotherapy is often favored for older adults who may not tolerate surgery well, people on blood thinners who face higher bleeding risks with excision, and patients with multiple small superficial lesions that would require several separate surgical procedures. The equipment is portable and the cost is low compared with operating-room procedures, which makes it accessible in rural or resource-limited settings.
The ideal lesion for cryotherapy is small (usually under two centimeters), superficial, well-defined at its edges, located away from critical nerves and cartilage-heavy structures where deep freezing is risky, and either a confirmed low-risk BCC or an actinic keratosis. If your dermatologist can see the entire boundary of the lesion clearly and the biopsy shows a non-aggressive subtype, freezing it is a reasonable and well-supported choice.
Cryotherapy is a poor fit when the tumor has ill-defined borders (the so-called morpheaform or infiltrative BCC subtypes), when it sits in a high-risk location like the central face or around the eyes, when it has already recurred after prior treatment, or when it is deep enough to potentially involve underlying structures. In those situations, Mohs surgery or standard excision with margin checks is safer.
The Immune System Angle
One of the more intriguing aspects of cryotherapy is what happens after the cells die. Unlike surgical excision, which physically removes the tumor, cryotherapy leaves the destroyed tissue in place. That dead tissue slowly breaks down and releases its contents into the surrounding area and bloodstream. Researchers have observed that this process can trigger an immune response, because the contents of cancer cells, normally hidden from the immune system behind intact cell membranes, are suddenly exposed.
Early research into cryosurgery for melanoma noted that the destroyed tumor remains in the body for about 72 hours, during which tumor-specific molecules come into contact with immune cells. The thinking is that immune cells encounter these molecules, recognize them as abnormal, and mount a response against any remaining tumor cells elsewhere.
15Clinics in Dermatology. Cryosurgery in the treatment of cutaneous malignant melanomaThis concept has recently attracted attention in the context of immunotherapy drugs. A proposal published in a cancer research journal suggested that if a patient’s immune system is first “primed” with checkpoint-inhibitor drugs (the same class of drugs that have transformed melanoma and lung cancer treatment), then cryotherapy applied to a tumor could release a flood of tumor-specific molecules that the now-unleashed immune system would attack aggressively, potentially targeting cancer at distant sites in the body as well.
16PubMed Central. Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced CancersThis remains a hypothesis with limited clinical validation so far, and it applies more to advanced internal cancers than to the kind of small skin cancers a dermatologist freezes off in the office. But it is a reminder that cryotherapy is not just a crude cold burn. The biological aftermath of freezing tissue is more complex than the procedure might suggest, and it is being explored as a potential partner for some of the most advanced cancer treatments in existence.
At-Home Freeze Products and Their Limits
Over-the-counter “freeze away” products marketed for wart removal use dimethyl ether or similar propellants that reach temperatures far warmer than liquid nitrogen. They are designed for common warts and should never be used on anything you suspect might be skin cancer. Even in a clinical setting, cryotherapy for cancer requires precise temperature control, sufficient depth of freeze, and clinical judgment about freeze duration and number of cycles. A drugstore aerosol cannot replicate that, and using one on a cancerous lesion risks destroying the surface while leaving deeper malignant cells intact, making subsequent diagnosis harder. If you have a spot you are worried about, it needs a biopsy first, not a freeze.
The same warning applies to the growing number of handheld cryotherapy devices marketed for cosmetic use. These devices are calibrated for superficial concerns like age spots and skin tags, not for the controlled destruction of malignant tissue. The gap between cosmetic-grade cold and cancer-treatment-grade cold is enormous, and no amount of repeated applications from a consumer device substitutes for a clinical assessment.
Follow-Up After a Freeze
One underappreciated aspect of cryotherapy for skin cancer is the follow-up schedule. Because there is no tissue specimen to confirm clear margins, the clinician relies on visual inspection over time to determine whether the treatment worked. Most protocols call for a follow-up visit a few weeks after treatment to assess healing, then periodic skin checks for at least five years. The five-year cure rates discussed earlier come from practices with rigorous follow-up schedules. If you skip your check-ups, a recurrence can grow undetected for months, potentially becoming harder to treat the second time around.
A retrospective study tracking squamous cell carcinoma in situ found that even surgical excision, with its confirmed margins, had a recurrence rate just under 1% over about eight years of follow-up. Cryotherapy came in at about 5%, and photodynamic therapy at 18%.
7Acta Dermato-Venereologica. A Retrospective Study of Treatment of Squamous Cell carcinoma In situThose numbers reinforce a pattern across the literature: cryotherapy is effective but generally not as effective as surgery, and the gap matters more as the cancer becomes more aggressive. For a low-risk superficial lesion in a patient who cannot easily undergo surgery, a 95-to-99% cure rate from a five-minute office procedure is excellent medicine. For a younger patient with a high-risk tumor and decades of life ahead, surgery’s extra percentage points of certainty are worth the inconvenience.